07:00 , Sep 19, 2011 |  BC Week In Review  |  Company News

Rare Disease Therapeutics sales and marketing update

Rare Disease Therapeutics launched Anascorp injection in the U.S. to treat scorpion stings by Centruroides scorpions. Instituto Bioclon S.A. de C.V. (Mexico City, Mexico) markets Anascorp as Alacramyn in Mexico and Colombia. The product consists...
07:00 , Aug 8, 2011 |  BC Week In Review  |  Clinical News

Anascorp regulatory update

FDA approved Anascorp from Rare Disease to treat scorpion stings by Centruroides scorpions. The product is expected to launch in early September, with a wholesale acquisition cost of $3,500 per vial. The company said most...
00:48 , Aug 5, 2011 |  BC Extra  |  Company News

FDA approves scorpion sting treatment

FDA approved Anascorp from Rare Disease Therapeutics Inc. (Franklin, Tenn.) to treat scorpion stings by Centruroides scorpions. The product is expected to launch in early September, with a wholesale acquisition cost of $3,500 per vial....
07:00 , May 25, 2009 |  BC Week In Review  |  Clinical News

Anascorp: Phase II/III data

Data from a double-blind, U.S. Phase II/III trial (AL-02/03) in 15 children ages 6 months to 18 years admitted to a pediatric ICU showed that IV Anascorp met the primary endpoint of resolution of the...